Related Experiment Video
Updated: Aug 13, 2026
Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Antifungal activity of saperconazole (R 66 905) in vitro
1Department of Microbiology, University of Leicester, UK.
Abstract:
Saperconazole, a novel orally active triazole antifungal, inhibited Candida spp., Aspergillus spp. and dermatophyte fungi in vitro. Its minimal inhibitory concentrations for Candida spp. and dermatophytes were relatively high, like those of comparable triazole antifungals, but all of the Aspergillus isolates tested were inhibited by less than 0.1 mg/l. Relative inhibition factors of saperconazole were in the range 31-76% for Candida isolates, 6-18% for Aspergillus isolates and 5-10% for dermatophytes. These figures predict a good inhibitory activity of saperconazole for all the fungi tested, with particularly strong activity against Aspergillus spp. and dermatophytes. Saperconazole inhibited hyphal branch formation in C. albicans at concentrations as low as 10(8) M.
Insights
Saperconazole, a novel triazole antifungal, shows potent in vitro activity against Aspergillus species and dermatophytes. This antifungal agent also demonstrated significant inhibition against Candida species.
Area of Science:
- Mycology
- Pharmacology
- Antimicrobial Agents
Background:
- Triazole antifungals are crucial for treating fungal infections.
- Emerging resistance necessitates the development of novel antifungal agents.
- Saperconazole represents a new triazole compound with potential therapeutic applications.
Purpose of the Study:
- To evaluate the in vitro antifungal activity of saperconazole.
- To compare saperconazole's efficacy against Candida, Aspergillus, and dermatophyte fungi.
- To assess the impact of saperconazole on fungal morphology.
Main Methods:
- In vitro susceptibility testing using minimal inhibitory concentrations (MICs).
- Determination of relative inhibition factors for various fungal species.
- Microscopic evaluation of fungal hyphal formation in response to saperconazole.
Main Results:
- Saperconazole demonstrated potent inhibition of Aspergillus spp. (MIC < 0.1 mg/l) and dermatophytes.
- Activity against Candida spp. was comparable to existing triazoles.
- Significant inhibition of hyphal branching in Candida albicans at low concentrations (10^-8 M).
Conclusions:
- Saperconazole exhibits broad-spectrum antifungal activity, with notable potency against Aspergillus and dermatophytes.
- Its efficacy suggests potential for treating a range of fungal infections.
- Further investigation into saperconazole's clinical utility is warranted.
